title: Position paper on laboratory testing for patients taking new oral anticoagulants. Consensus document of FCSA, SIMeL, SIBioC and CISMEL1).
abstract: At variance with vitamin K antagonists, the new oral anticoagulants(NOAs) can be prescribed at fixed dosage without adjustment by laboratory testing. However, this does not necessarily mean that the laboratory does not play a role for their management. This position paper represents the consensus document of three Italian scientific societies dealing with laboratory issues in thrombosis and hemostasis. It is aimed at reviewing: 1) which test(s) should be used to evaluate the anticoagulant effect of each of the NOAs presently available(i.e., dabigatran, rivaroxaban and apixaban); 2) the patients to be investigated; and 3) the timing of investigation.
authors.affiliation: Department of Clinical Sciences and Community Health, Universit à degli Studi di Milano, Milan , Italy. armando.tripodi@unimi.it
authors.forename: Armando
authors.initials: A
authors.lastname: Tripodi
authors.forename: Giancarlo
authors.initials: G
authors.lastname: Di Iorio
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Lippi
authors.forename: Sophie
authors.initials: S
authors.lastname: Testa
authors.forename: Cesare
authors.initials: C
authors.lastname: Manotti
mesh_terms: D000284:Administration, Oral; D000925:Anticoagulants / Q000008:administration & dosage*; D006487:Hemostasis; D006801:Humans; D013927:Thrombosis / Q000517:prevention & control
chemical_list: D000925:Anticoagulants